Evaluation of docetaxel-loaded intravenous lipid emulsion: pharmacokinetics, tissue distribution, antitumor activity, safety and toxicity.
OBJECTIVE
The purpose of this study was to carry out a detailed evaluation of an intravenous lipid emulsion for docetaxel (DLE) without Tween 80 before clinical administration.


METHODS
The pharmacokinetics in rats and beagle dogs, tissue distribution, antitumor activity, safety test and toxicity of DLE have been investigated systematically to evaluate the formulation and compared with Taxotere(R) (DS).


RESULTS
The pharmacokinetic study in rats revealed that DLE exhibited higher plasma concentrations and AUC than DS, and a good correlation was observed between AUC and dose, while, in beagle dogs, the DLE was bioequivalent to DS. The tissue distribution study showed that the profiles of the two formulations were similar, indicating the DLE did not change the distribution of docetaxel in vivo. Furthermore, DLE was as safe as DS in the safety investigation and displayed significant antitumor activities against the A549, BEL7402 and BCAP-37 cell lines in nude mice, similar to DS. The corresponding results of the long-term toxic study demonstrated the DLE was less toxic than DS, and the toxic effects could be reversed.


CONCLUSIONS
The DLE investigated in this paper was found to be an attractive new formulation and an appropriate choice for the clinical administration of docetaxel.
Zhao
Mingming
M
Department of Pharmaceutics, Shenyang Pharmaceutical University, Wenhua Road 103, Shenyang, 110016, Liaoning Province, People's Republic of China.
Su
Min
M
Lin
Xia
X
Luo
Yanfei
Y
He
Haibing
H
Cai
Cuifang
C
Tang
Xing
X
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000494:pharmacology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D000077143:Docetaxel; D004285:Dogs; D005217:Fat Emulsions, Intravenous; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D051379:Mice; D011817:Rabbits; D051381:Rats; D017208:Rats, Wistar; D012015:Reference Standards; D012449:Safety; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000494:pharmacology*; D014018:Tissue Distribution
D000970:Antineoplastic Agents; D005217:Fat Emulsions, Intravenous; D043823:Taxoids; D000077143:Docetaxel